Eton Pharmaceuticals Stock Price, News & Analysis

Eton Pharmaceuticals (Nasdaq: ETON) said members of its executive leadership will host 1x1 meetings at the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025 in New York, NY.

Investors or institutional representatives seeking a meeting are instructed to contact their Craig-Hallum institutional sales representative to schedule a 1x1.

Eton Pharmaceuticals (Nasdaq: ETON) reported Q3 2025 product sales of $22.5 million, a 129% year-over-year increase and the 19th consecutive quarter of sequential product sales growth. GAAP EPS was $(0.07), non-GAAP EPS was $0.04, and Adjusted EBITDA was $2.9 million. The company had $37.1 million in cash and generated $12.0 million of operating cash flow in the quarter.

Pipeline and commercial updates include an NDA for ET-600 accepted with a PDUFA date of February 25, 2026, GALZIN relaunch ahead of plan, progress toward KHINDIVI label expansion with a planned bioequivalence study, and an ET-700 pilot PET study scheduled to begin in Q1 2026.

Eton Pharmaceuticals (Nasdaq: ETON) announced it will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and live audio webcast at 4:30 p.m. ET (3:30 p.m. CT) to discuss results and take live and emailed investor questions.

Investors may submit questions to investorrelations@etonpharma.com. The live webcast is available on the company investor website at https://ir.etonpharma.com/. An archived webcast will be posted approximately two hours after the event and remain available for 30 days.

Eton Pharmaceuticals (Nasdaq: ETON), a pharmaceutical company specializing in rare disease treatments, announced its participation in the 2025 Wells Fargo Healthcare Conference. The company's executive team will be available for one-on-one meetings during the conference, which takes place from September 3-5, 2025 in Boston, MA.

Interested parties can schedule meetings through their Wells Fargo institutional sales representatives.

Eton Pharmaceuticals (Nasdaq: ETON) reported strong Q2 2025 financial results, with product sales reaching $18.9 million, marking a 108% growth over Q2 2024 and the 18th consecutive quarter of sequential growth. The company posted a GAAP EPS of $(0.10) and non-GAAP EPS of $0.03.

Key highlights include the FDA approval and launch of KHINDIVI™, their eighth commercial product, reaching 100 active INCRELEX® patients ahead of schedule, and strong performance of ALKINDI SPRINKLE® and GALZIN. The company expects to achieve an $80 million annual revenue run rate in Q3 2025, one quarter ahead of previous guidance.

Financial metrics show gross profit of $11.9 million (75% adjusted margin) and Adjusted EBITDA of $3.1 million. The company maintains a strong cash position of $25.4 million and generated $8.0 million in operating cash flow during the quarter.

Eton Pharmaceuticals (Nasdaq: ETON), a pharmaceutical company specializing in rare disease treatments, has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025.

The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss the results. Investors can participate via phone using the dial-in numbers (800) 715-9871 or (646) 307-1963 with Conference ID 5899895, or through the webcast available on Eton's investor relations website. Management will address both live questions and emailed inquiries sent to investorrelations@etonpharma.com.

Eton Pharmaceuticals (Nasdaq: ETON) announced that the FDA has accepted its New Drug Application (NDA) for ET-600, a proprietary desmopressin oral solution. The FDA has assigned a PDUFA target action date of February 25, 2026 for the review.

ET-600 aims to address unmet needs in pediatric endocrinology by providing a liquid formulation alternative to fractional tablets and compounded suspensions. The product has patent protection through 2044 and, if approved, would be the only oral liquid option available in the market. Eton is preparing for a potential commercial launch in Q1 2026.

Eton Pharmaceuticals (Nasdaq: ETON), a company focused on rare disease treatments, announced its inclusion in the Russell 2000® and Russell 3000® Indexes effective June 27, 2025. This addition marks a significant milestone for the company, reflecting its strong performance and shareholder value creation over the past year.

CEO Sean Brynjelsen highlighted this achievement as an opportunity to increase the company's visibility among investors while continuing their mission of developing treatments for ultra-rare conditions.

Eton Pharmaceuticals (ETON) has received FDA approval for KHINDIVI™, the first and only FDA-approved hydrocortisone oral solution for pediatric patients aged 5+ with adrenocortical insufficiency. The 1mg/ml solution offers precise dosing without the need to split tablets, requiring no refrigeration or mixing. Commercial launch is expected by June 2nd, with distribution through Anovo specialty pharmacy. KHINDIVI complements Eton's existing ALKINDI SPRINKLE® product line, with the company projecting combined peak sales exceeding $50 million. The U.S. market includes over 5,000 potential patients aged 5-17. The Eton Cares Program will provide prescription support and $0 co-pays for qualifying patients.